Delivery Order SPE2DB25D7068-SPE2DB25FTWVQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,645.80 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone otic suspension (7.5mL) on November 20, 2025, with completion expected by November 21, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle valued through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,244.47 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML on June 18, 2025, with completion scheduled for June 20, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value pharmaceutical supply transaction...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,594.26 for Ciprofloxacin-Dexamethasone otic suspension (7.5mL) with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a single transaction under the company's broader...
- The Defense Logistics Agency awarded a delivery order valued at $1,523.36 to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Ciprofloxacin-Dexamethasone Otic Suspension 7.5ml, with completion targeted for June 2, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency (DLA) awarded a $1,625.90 delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML, with an ultimate completion date of July 30, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,780.32 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5ML) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $2,579.27 to AmerisourceBergen Drug Corp for the supply of Ciprofloxacin-Dexamethasone Otic Suspension in 7.5mL units. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order is scheduled for completion by November 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML, with a ceiling value of $1,592.69. This non-competitive, firm fixed price delivery order was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,226.40 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone otic suspension (7.5mL) on December 12, 2025, with a completion deadline of December 15, 2025. This firm fixed price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order is...
- The Defense Logistics Agency awarded a $1,097.53 delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5mL) under a firm fixed price contract type. The award, issued on August 5, 2025, with completion targeted for August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical supply delivery. This delivery order is issued...
- SPE2DB25D7068Indefinite Delivery Contract
- SPE2DB25D7068-SPE2DB25FTWVQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,594.26 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML on May 22, 2025, with an ultimate completion date of May 23, 2025. This firm fixed price delivery order was competitively awarded without any set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The pharmaceutical product being delivered under this order supports the Defense Health Agency and other federal healthcare systems as part of DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 5/22/25 |